{"id":19365,"date":"2021-05-28T08:04:41","date_gmt":"2021-05-28T12:04:41","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=19365"},"modified":"2021-05-29T09:05:24","modified_gmt":"2021-05-29T13:05:24","slug":"pipeline-update-dlocal-goes-live-eight-ipos-file","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/pipeline-update-dlocal-goes-live-eight-ipos-file\/","title":{"rendered":"Pipeline Update: DLocal goes live, Flood of IPO Filings!"},"content":{"rendered":"

TERMS ADDED<\/strong><\/span><\/p>\n

Company: DLocal Limited
\nSymbol: DLO
\nDescription: dLocal is focused on making the complex simple, redefining the online payments experience in emerging markets.
\nShares: 29.4 million
\nPrice Range: $16.00-$18.00
\nTrade Date: Thursday, 6\/3
\nUnderwriter(s): JP Morgan, Goldman Sachs, Citigroup, Morgan Stanley, BofA Securities, HSBC, UBS Investment Bank
\nLink to Prospectus: Terms Added: 5-24-21
\nNote: 25.0mm shares being offered by selling shareholders<\/p>\n

NEW FILINGS<\/strong><\/span><\/p>\n

Company: Sprinklr, Inc.
\nSymbol: CXM
\nDescription: Sprinklr empowers the world\u2019s largest and most loved brands to make their customers happier.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Morgan Stanley, JP Morgan, Citigroup, Barclays, Wells Fargo
\nCo-Manager(s): JMP Securities, KeyBanc Capital, Oppenheimer, Stifel, William Blair
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: D-MARKET Electronic Services & Trading
\nSymbol: HBX
\nDescription: They are a leading commerce platform in Turkey and, in 2020, we connected 33 million members, 9 million Active Customers and a fast growing base of approximately 45 thousand Active Merchants.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Morgan Stanley, JP Morgan, Goldman Sachs, BofA Securities, UBS Investment Bank
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: Miromatrix Medical, Inc
\nSymbol: MIRO
\nDescription: They are a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients\u2019 lives.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Craig Hallum
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $20m<\/p>\n

Company: Century Therapeutics, Inc
\nSymbol: IPSC
\nDescription: They are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: JP Morgan, BofA Securities, SVB Leerink, Piper Sandler
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: EverCommerce Inc
\nSymbol: EVCM
\nDescription: They are a leading provider of integrated, vertically-tailored software-as-a-service (SaaS) solutions for service-based small- and medium-sized businesses, or service SMBs.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, JP Morgan, RBC Capital, KKR, Barclays, Deutsche Bank, Jefferies, Evercore ISI, Oppenheimer, Piper Sandler, Raymond James, Stifel
\nCo-Manager(s): Canaccord Genuity, JMP Securities, Academy Securities, Loop Capital, R. Seelaus & Co., Ramirez & Co.
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: Codex DNA, Inc.
\nSymbol: DNAY
\nDescription: They believe that they are a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or \u201cwrite\u201d high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBDA
\nUnderwriters: Jefferies, Cowen, KeyBanc Capital
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: Ambrx Biopharma Inc
\nSymbol: AMAM (NYSE)
\nDescription: They are a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using our proprietary expanded genetic code technology platform that allows us to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Goldman Sachs, BofA Securities, Cowen
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: First Advantage Corporation
\nSymbol: FA
\nDescription: First Advantage is a leading global provider of technology solutions for screening, verifications, safety, and compliance related to human capital.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriters: Barclays, BofA Securities, JP Morgan, Citigroup, Evercore ISI, Jefferies, RBC Capital, Stifel, HSBC
\nCo-Manager(s): Citizens Capital Markets, KKR, MUFG, Loop Capital, R. Seelaus & Co., Ramirez & Co., Roberts & Ryan
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: AiHuiShou International Co. Ltd.
\nSymbol: RERE
\nDescription: They are the largest pre-owned consumer electronics transactions and services platform in China in terms of GMV for electronics and the number of devices transacted by merchants and consumers.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs, BofA Securities, China Renaissance
\nCo-Manager(s): GTJA, CLSA, Tiger Brokers
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: Verve Therapeutics, Inc.
\nSymbol: VERV
\nDescription: They are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): JP Morgan, Jefferies, Guggenheim Securities, William Blair
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: Cyteir Therapeutics, Inc.
\nSymbol: CYT
\nDescription: They are a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): JP Morgan, Morgan Stanley, BofA Securities
\nCo-Manager(s): Wedbush PacGrow
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: Doximity, Inc.
\nSymbol: DOCS
\nDescription: They are the leading digital platform for U.S. medical professionals, as measured by the number of U.S. physician members, with over 1.8 million medical professional members as of March 31, 2021.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Morgan Stanley, Goldman Sachs, JP Morgan
\nCo-Manager(s): Piper Sandler, William Blair, Canaccord Genuity, Needham & Co., Raymond James, SVB Leerink
\nLink to Prospectus: Filed: 5-28-21
\nListed Cash Raise: $100m<\/p>\n

Company: Full Truck Alliance Co. Ltd.
\nSymbol: YMM
\nDescription: They have transformed China\u2019s road transportation industry by pioneering a digital, standardized and smart logistics infrastructure across the value chain.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Morgan Stanley, CICC, Goldman Sachs, UBS Investment Bank, Huatui Securities, Citigroup, Nomura
\nCo-Manager(s): China Renaissance, CLSA Limited
\nLink to Prospectus: Filed: 5-27-21
\nListed Cash Raise: $100m<\/p>\n

Company: Lyell Immunopharma, Inc.
\nSymbol: LYEL
\nDescription: They are a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs, BofA Securities, JP Morgan, Morgan Stanley
\nLink to Prospectus: Filed: 5-25-21
\nListed Cash Raise: $150m<\/p>\n

Company: Tremor International Ltd.
\nSymbol: TRMR
\nDescription: They are a global company offering an end-to-end software platform that enables advertisers to reach relevant audiences and publishers to maximize yield on their digital advertising inventory.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): RBC Capital, Stifel, JMP Securities, Needham, Raymond James
\nLink to Prospectus: Filed: 5-25-21
\nListed Cash Raise: $100m
\nTheir ordinary shares trade on the AIM (London Stock Exchange)<\/p>\n

Company: Unicycive Therapeutics Inc.
\nSymbol: UNCY
\nDescription: They are a biotechnology company dedicated to developing treatments for certain medical conditions.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Roth Capital
\nCo Managers: Kingswood Capital
\nLink to Prospectus: Filed: 5-21-21
\nListed Cash Raise: $34.5m<\/p>\n

Company: KANZHUN LIMITED
\nSymbol: BZ
\nDescription: They created a mobile-native product that promotes instant direct chats between Bosses and job seekers, delivers accurate matching results, and is powered by proprietary AI algorithms and big data insights.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, UBS Investment Bank
\nCo Managers: China Renaissance, Haitong International, FUTU, Tiger Brokers
\nLink to Prospectus: Filed: 5-21-21
\nListed Cash Raise: $100m<\/p>\n

Company: Core & Main, Inc.
\nSymbol: CNM (NYSE)
\nDescription: They are a leading specialized distributor of water, wastewater, storm drainage and fire protection products, and related services, to municipalities, private water companies and professional contractors across municipal, non-residential and residential end markets nationwide.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs, Credit Suisse, JP Morgan, BofA Securities, Baird, Citigroup, RBC Capital, Barclays, Deutsche Bank
\nCo Managers: Truist Securities, Nomura, Natixis, Drexel Hamilton, R. Seelaus & Co., Ramirez & Co., Siebert Williams Shank
\nLink to Prospectus: Filed: 5-21-21
\nListed Cash Raise: $100m<\/p>\n

Company: Convey Holding Parent, Inc.
\nSymbol: CNVY (NYSE)
\nDescription: Convey Health is a leading healthcare platform that utilizes technology and processes to improve government-sponsored health plans, including Medicare Advantage (\u201cMA\u201d).
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): BofA Securities, Goldman Sachs, JP Morgan, Barclays
\nCo Managers: TPG Capital BD LLC, Truist Securities, Canaccord Genuity
\nLink to Prospectus: Filed: 5-21-21
\nListed Cash Raise: $100m<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":12986,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[2058,1536],"tags":[],"class_list":["post-19365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-spotlight","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/19365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=19365"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/19365\/revisions"}],"predecessor-version":[{"id":19377,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/19365\/revisions\/19377"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media\/12986"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=19365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=19365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=19365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}